CD96 expression has been detected in AML patients with mutated WT1 and was associated with adverse clinical and biological features, such as higher white blood cell counts and percentage of blood blasts, and FLT3-ITD [92]. The gene discussed is FLT3; the disease is acute myeloid leukemia.